Flow-dependency of exhaled nitric oxide in children with asthma and cystic fibrosis by Kroesbergen, A. et al.
Flow-dependency of exhaled nitric oxide in children with asthma
and cystic fibrosis
A. Kroesbergen#,*, Q. JoÈbsis#, E.H.D. Bel*, W.C.J. Hop**, J.C. de Jongste#
Flow-dependency of exhaled nitric oxide in children with asthma and cystic fibrosis. A.
Kroesbergen, Q. JoÈbsis, E.H.D. Bel, W.C.J Hop, J.C. de Jongste.#ERS Journals Ltd 1999.
ABSTRACT: The concentration of nitric oxide in exhaled air, a marker of airway
inflammation, depends critically on the flow of exhalation. Therefore, the aim of this
study was to determine the effect of varying the flow on end-expiratory NO con-
centration and NO output in children with asthma or cystic fibrosis (CF) and in
healthy children.
Nineteen children with stable asthma, 10 with CF, and 20 healthy children exhaled
from TLC while controlling expiratory flow by means of a biofeedback signal at
approximately 2, 5, 10 and 20% of their vital capacity per second. NO was measured
in exhaled air with a chemiluminescence analyser. Comparisons between the three
groups were made by analysing the NO concentration at the endexpiratory plateau
and by calculating NO output at different flows.
Exhaled NO decreased with increasing flow in all children. Children with asthma
had significantly higher NO concentrations than healthy children, but only at the
lowest flows. Asthmatics using inhaled steroids (n=13) tended to have lower median
exhaled NO than those without steroids. The slope of linearized (log-log transformed)
NO/flow plots was significantly steeper in asthmatics than in healthy controls. CF
patients had a significantly lower NO concentration and output over the entire flow
range studied, compared to asthmatic and control subjects, with a similar NO/flow
slope as control subjects.
In conclusion, the nitric oxide concentration in exhaled air is highly flow-dependent,
and the nitric oxide-flow relationship differs between asthmatics versus cystic fibrosis
patients and control subjects. Assessment of the nitric oxide/flow relationship may
help in separating asthmatics from normal children.
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Nitric oxide (NO) has an important regulatory role in the
lung and has been implicated in the pathophysiology of
airway diseases [1]. During the past few years, NO in ex-
haled air has been examined as a marker of airway in-
flammation. NO can be measured directly in exhaled air
[2]; increased levels have been documented in several in-
flammatory airway disorders, including asthma. How-
ever, patients with cystic fibrosis (CF) were found to have
similar or lower levels compared to normal subjects,
either in nasal or in oral air [3, 4]. Both an increase and a
decrease in the level of NO in exhaled air may therefore
be taken as potential markers of disease and exhaled NO
may be clinically useful in diagnosing and monitoring
airway diseases.
Values of exhaled NO reported by various investigators
differ greatly [5]. This can be explained by differences in
the methods of measurement. NO in exhaled air depends
on airflow [6]. Since NO is continuously released into the
airway lumen, high concentrations will result when ex-
halation is slow, and low concentrations when exhalation
is fast. It is unknown to what extent disease affects the
flow-dependency of NO in exhaled air. Recently, Euro-
pean Respiratory Society task force published guidelines
on measurement of exhaled NO, emphasizing that nor-
malization for flow is vital [7]. Until now, studies on
exhaled NO in children did not take flow-dependency
into account. Therefore, the aim of this study was to
determine the effect of varying the flow of exhalation on
the NO concentration in exhaled air, and to examine the
concentration of NO and the NO/flow relationship in
normal subjects, asthmatic children and children with CF.
Patients and methods
Study population
Patients were recruited from the outpatient clinic for
paediatric respiratory medicine of Sophia Children's Hos-
pital, and healthy control subjects were selected from a
school population according to the following criteria. Asth-
ma was diagnosed according to international guidelines,
based on a typical clinical history [8]. In addition, all asth-
matic children had bronchial hyperresponsiveness (pro-
vocative dose of inhaled methacholine that produced a
20% fall in forced expiratory volume in one second of
<150 mg) and allergy, as previously documented by radio
allergosorbent test class $2 for at least one common
airborne allergen. All asthmatics were clinically stable for
at least 2 weeks before the measurement, and all were
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lifelong nonsmokers. Thirteen used inhaled corticoster-
oids (median daily dose 400 mg, range 100±1,000 mg.
day-1), all used bronchodilators on demand. CF was
diagnosed on the basis of typical clinical symptoms,
abnormal sweat test and the identification of two CF
mutations. All CF patients had been clinically stable for at
least 2 weeks prior to the measurements. One CF patient
used inhaled corticorsteroids. Healthy children were
selected on the basis of no history of allergic respiratory
disease and eczema, as defined by negative answers to the
International Study on Allergies and Asthma in Child-
hood (ISAAC) core questionnaires, no symptoms of
respiratory infection during the past 2 weeks, never
smoked and had no other chronic disease. All had a nor-
mal lung function. None used medication. All subjects
underwent flow volume curve measurements, using a
heated Lilly-type pneumotachograph (Jaeger, WuÈrzburg,
Germany); results were expressed as per cent predicted
[9]. The study was approved by the hospital ethics com-
mittee and informed consent was obtained from all
subjects.
Nitric oxide measurement
NO was measured in exhaled air with a Sievers 280
chemiluminescence analyser (Sievers, Boulder, CO, USA)
with a sensitivity of <0.1 parts per billion (ppb) and a
detection range of <0.1±500,000 ppb. The sampling flow
was 0.2 L.min-1, the response time was 0.2 s and data were
displayed with a lag time of ~2 s. The analyser was cali-
brated regularly according to the manufacturer's guide-
lines, employing certified calibration gases containing 0
ppb, 100 ppb and 9 parts per million (ppm) NO (Hoek-
Loos, Barendrecht, the Netherlands). The measurement
circuit consisted of a mouthpiece connected to a two-way
nonrebreathing valve (Rudolph Inc., Kansas City, MO,
USA) through which the subjects inhaled ambient air while
seated and without wearing a noseclip. After inserting the
mouthpiece, the subjects inhaled to total lung capacity
(TLC and immediately exhaled for as long as possible into
a wide bore tube, with an in-line flow resistance (model
#7100 R-20, 20 cmH2O.L
-1.s; Rudolph Inc). This was
performed at flows corresponding to 2, 5, 10 and 20% of
the subject's vital capacity (VC) per second. A fine bore
teflon tube continuously sampled the exhaled air from a
side-port directly after the mouthpiece at 0.20 L.min-1 for
the measurement of NO. Airflow was measured by a
heated Lilly-type pneumotachograph (Jaeger), mounted
after the resistance. Flow was displayed on a video screen
as a moving block that could be seen by the subject and
should be kept between two arrows. This biofeedback
system made it possible to standardize exhaled flow to an
individually set value. An end-expiratory flow-plateau of
at least 3 s for the different flows (2 s for the highest flow)
was the end-point of the measurement. A plateau was
defined as a flow tracing which varies less than 10%
around the target flow. The test was performed in triplicate
for every flow and average NO values at the flow plateau
were calculated. Between the different manoeuvres, a rest-
ing period of 2±3 min was maintained for equilibration of
resting ventilatory conditions. All tests were performed
with ambient NO concentrations <5 ppb.
Data analysis
Both the NO signal and the flow signal were fed into a
computer at a sampling rate of 20 Hz. Values of NO and
flow were obtained at each attempt by calculating the
mean value in defined time intervals of 3 or 2 s, using
custom-made software, and individual means were cal-
culated from triplicate NO and flow (L.s-1) values. NO
output, defined as the product of mean NO and flow (L.
s-1), was calculated for each target flow, and expressed in
nL.min-1. NO concentrations and NO output values were
lognormally distributed and compared for each of four
target flows between patient groups and healthy control
subjects by means of the Mann-Whitney test. Plots of NO
versus flow in L.s-1 were linearized by log-log transforma-
tion, and regression analysis for repeated measurements
was used to compare NO/flow slopes for the three groups
[10]. The effect of normalizing flow for VC was ev-
aluated by plotting individual NO values versus flow,
either expressed as %VC.s-1 or as mL.s-1, in log-log
normalized plots. Standard deviations of the intercepts
of individual regression lines in both types of NO/flow
plots at an arbitrary flow of log (7% VC.s-1) and log (300
mL.s-1) were compared. The level of significance was set
at p=0.05 (two sided).
Results
Patient characteristics are given in table 1. The mea-
surements were well tolerated. Two or three reproducible
NO values for each flow rate were always obtained within
five attempts. The NO level at the end-expiratory plateau
decreased with increasing flows in all children. Median
values of NO concentration and NO output, as well as the
median absolute flows at which these were obtained, are
given in table 2. Individual NO-flow relationships for the
three groups are shown in figure 1. Asthmatics had higher
median NO concentrations than control subjects, but a
significant difference was only present at the lowest end
of the flow spectrum. Likewise, median NO output was
higher in asthmatics than in control subjects at the lower
end of the flow range, but the differences were not sig-
nificant. Strikingly, the variation in exhaled NO was
much larger in asthmatics than in healthy children, Med-
ian NO values were higher in asthmatics without cor-
ticosteroids than in those with steroids (12.1, 6.1, 4.2 and
2.7 ppb versus 16.7, 17.1, 11.1, and 6.8 ppb at flows of 2,
Table 1. ± Patient characteristics
Healthy control
subjects
Asthmatic
children
CF patients
Subjects n 20 19 10
Sex M/F 12/8 9/10 5/5
Age months 16510
(149±180)
15422
(116±198)
14322
(114±183)
FVC % 10112
(82±122)
10112
(76±121)
9413
(78±126)
FEV1 % 10312
(85±126)
8816
(54±116)
8417
(52±110)
Data are meanSD (ranges). CF: cystic fibrosis; M: male; F:
female; FVC: forced vital capacity; FEV1: forced expiratory
volume in one second.
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5, 10 and 20% of VC, respectively), but none of the
differences reached statistical significance. CF patients
had a significantly lower median NO concentration and
output than healthy control subjects and asthmatics over
the entire flow range tested. Double logarithmic trans-
formation of flow and NO resulted in a linear NO/flow
relationship for each individual in all three groups within
the flow range studied (fig. 1). Using regression analysis
of log NO versus log flow, with flow expressed as mL.s-1,
it appeared that the average decrease of NO per doubling
of flow in asthmatics was 33% (95% confidence interval
(CI) 29±37%). For healthy children and CF patients, these
figures were 21% (95% CI 18±24%), and 24% (95% CI
10±36%), respectively. The slope of NO versus flow was
significantly steeper for the asthmatic patients than for the
control subjects (p=0.003). These results were the same,
irrespective of whether flow was expressed as mL.s-1 or
as %VC.s-1.
For each group, whether baseline lung function in-
fluenced the outcomes was investigated. It appeared that
the NO concentration, NO output and slopes were not
significantly affected by either forced expiratory volume in
one second (FEV1) or forced vital capacity (FVC). The
asthmatic patients who used steroids (n=13) had NO levels
that were slightly lower, but not significantly different from
those without steroids. Within groups, age did not correlate
with exhaled NO values.
Normalizing flow for lung and airway size by ex-
pressing it as a percentage of VC.s-1 instead of mL.s-1 did
not reduce the standard deviation of the intercepts of the
individual regression lines at an arbitrary flow of 7% VC.
s-1 or 300 mL.s-1 within groups (fig. 2).
Discussion
The present study confirms that the NO concentration in
exhaled air rises with decreasing flow, and shows that the
NO/flow relationship differs between children with asthma
on the one hand, and CF patients and healthy children on
the other hand. The clinical implication of these results is
that the measurement of NO clearly distinguished between
the different disease states at low flow rates, and that not
only NO concentration at a fixed flow rate, but also the
slope of the NO/flow relationship discriminates between
asthmatics and healthy subjects or CF patients.
This study is the first to quantify the effect of varying the
flow rate on the NO concentration in exhaled air in chil-
dren and to establish the effect of different disease states on
the NO/flow relationship. SILKOFF et al. [6] recruited a
group of healthy adult volunteers (age 16±50 yrs) for their
study of the flow-dependency of end-expiratory NO in
exhaled air. SATO et al. [11] studied the effect of the du-
ration of exhalation on the NO levels in exhaled air in
healthy and asthmatic adults. Exhaled air was collected in
a reservoir and the subjects wore a noseclip. Hence, not
only the plateau level of NO, but also the initial peak
level, and probably contamination with nasal air con-
tributed to the results of this study. BYRNES et al. [12]
studied the mean peak concentration of NO at different
flow rates in adults. However, peak NO concentrations
reflect the NO concentration in the anatomical dead
space, contaminated by nasal NO; noseclips may have
enhanced nasal contamination. The increase of NO in
exhaled air with decreasing flow observed in the current
study matches the results by SILKOFF et al. [6] and BYRNES
et al. [12], and confirms that the NO levels in exhaled air
in well-controlled asthmatics are only slightly higher than
in healthy subjects.
The results of the present study might have been biased
by methodological aspects. Firstly, it could be argued that
the flow resistance used was not high enough to close the
soft palate, leading to nasal contamination. In a study in
adults, no contamination of NO from the nasal cavity was
observed with a flow resistance of at least 3 cmH2O.L
-1.s
[13]. No similar studies have been published for children.
The flow resistance used in the current study was 20
cmH2O.L
-1.s, and it is therefore likely that nasal con-
tamination of the NO concentration in exhaled air was
effectively prevented at least at flow rates >150 mL.s-1,
corresponding to oral pressures >3 cmH2O.L-1.s. How-
ever, the mean flows at 2%, and sometimes at 5% of
VC.s-1 were below this value, and therefore some nasal
contamination at the lowest flows cannot be excluded.
Table 2. ± Exhaled nitric oxide (NO) in children with and without asthma or cystic fibrosis (CF)
Healthy control subjects
(n=20)
Asthmatic children
(n=19)
CF patients
(n=10)
Exhaled NO ppb
At 2% VC.s-1 8.8 (5.4±23.6) 12.1 (1.7±75.1)* 3.5 (0.4±9.9)**
At 5% VC.s-1 5.9 (3.6±13.9) 6.4 (1.0±36.8) 1.9 (0.6±4.3)**
At 10% VC.s-1 4.8 (2.6±10.0) 4.6 (1.1±21.3) 1.5 (0.2±3.6)**
At 20% VC.s-1 4.4 (3.2±6.6) 3.2 (0.9±18.5) 1.4 (0.4±2.6)**
NO output nL.min-1
At 2% VC.s-1 39 (17±107) 64 (6±271) 11 (1±35)**
At 5% VC.s-1 65 (35±195) 72 (7±320) 15 (3±40)***
At 10% VC.s-1 102 (60±241) 109 (15±357) 27 (5±45)***
At 20% VC.s-1 190 (113±368) 151 (24±650) 43 (16±83)***
Actual flows mL.s-1
At 2% VC.s-1 70 (40±120) 60 (30±300) 52 (30±200)
At 5% VC.s-1 170 (100±300) 150 (70±270) 123 (90±210)
At 10% VC.s-1 341 (200±610) 283 (160±540) 272 (160±410)
At 10% VC.s-1 716 (420±1210) 570 (340±1070) 556 (360±740)
All data are median (range). VC: vital capacity; ppb: parts per billion. *: p<0.05; **: p<0.001; ***: p<0.0001 compared to control
subjects and asthmatics.
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This has not necessarily introduced a bias, as it would
affect results in asthmatic and control subjects similarly.
Secondly, the study assessed whether normalizing ex-
piration flow as a percentage of the patient's VC has ad-
vantages above comparing fixed flows, which do not take
differences in lung and airway size into account. The
results showed that normalization of expiration flow for the
VC is not very important when comparing exhaled NO in
children of different sizes. It may still be that in larger
groups within-group variation is smaller with measurement
at a lung size-dependent flow, but this remains to be
shown. Alternatively, standardizing for the lung volume at
which NO is measured may increase the accuracy of NO
measurements. However, the present study did not ex-
plicitly define the lung volume at which results were ob-
tained.
A final source of error may be the repeated performance
of expiratory manoeuvres. All children performed a num-
ber of deep inspirations and expirations and, since this
study, it has been shown that forced manoeuvres cause a
decreased NO output [14]. The NO levels may therefore
have been underestimated. It is thought that such an effect
may have been small, as no decreasing trend was obvious
for the repeated measurements at a given target flow.
The group of children with asthma had a higher median
level of NO in exhaled air, which may be due to residual
chronic airway inflammation despite steroid treatment, and
to the fact that a number of children did not use steroids
and, indeed, tended to have higher NO values than those
who did.
CF patients have lower exhaled NO than healthy sub-
jects. As inflammation is invariably present in CF airways
[15], it has been speculated that the increased amount of
thick bronchial mucus in patients with CF may favour
retention and metabolism of NO in airway liquids [4].
That increased NO production takes place in CF airways
is supported by data demonstrating increased nitrite lev-
els in breath condensate, despite normal NO in exhaled
air, in a group of older CF patients [16]. The results of the
present study confirm that increased NO levels in in-
flamed CF airways are not reflected by an increase in
exhaled NO [3, 4, 16]. In contrast to earlier reports, sig-
nificantly lower orally exhaled NO values in CF than in
control subjects were found. This may partly be due to
important differences in methodology: no expiratory res-
istance [4], tidal breathing versus single controlled expir-
ation [3] and older, more severe patients [16] in previous
studies.
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Fig. 1. ± Exhaled nitric oxide (NO) versus flow endexpiratory plateaus
in a) healthy children (n=20), b) children with asthma (n=19) and c)
children with cystic fibrosis (n=10). Each line represents one child. Both
exhaled NO and endexpiratory flow were measured on a logarithmic
scale. ppb: parts per billion.
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Fig. 2. ± Log-log transformed plots of exhaled nitric oxide (NO) of 20
healthy children versus flow normalized as a percentage of the patients'
vital capacity (VC) per second. Comparison with fig. 1a shows that
normalization of flow for lung size did not result in a reduced variation,
confirmed by statistical analysis, showing a similar standard deviation of
the intercepts of individual regression lines at arbitrary flows of 7% of
VC and 300 mL.s-1 (see Results section.)
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In conclusion, this study shows that differences in ex-
haled nitric oxide between asthmatics, cystic fibrosis pa-
tients and healthy children are greatest at low flows; the
linearized NO/flow relationship is steepest in asthmatics.
These results indicate that accurate standardization of low
flow rates is necessary; a convenient target flow could be
100 mL.s-1. For firm recommendations, larger groups
should be studied and a cutoff level determined for a given
purpose, e.g. detection of disease. For diagnostic purposes
in children, nitric oxide measurements in exhaled air at
different flow rates may prove an additional new tool for
the differential diagnosis of airway diseases, especially
asthma and cystic fibrosis.
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